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Abstract
Background: Serodiscordance exists when the known HIV result of one member of a couple pair is positive while
that of his/her partner is negative. In sub-Saharan Africa, in stable long-term couple partnerships (married or
cohabiting), serodiscordance is a growing source of HIV-transmissions. This study aimed to ascertain across Nigeria,
serodiscordance prevalence, partner HIV status disclosure and explore associations between suspected determinants
and serodiscordance among PMTCT enrolled HIV positive pregnant women and their partners.
Methods: A retrospective Quality of Care performance evaluation was conducted in July 2013 among 544 HIV
positive pregnant enrolees of PMTCT services in 62 comprehensive facilities across 5 of Nigeria’s 6 geo-political
zones. Data of client-partner pairs were abstracted from pre-existing medical records and analysed using chi-square
statistics and logistic regression.
Results: A total of 544 (22 %) of 2499 clients with complete partner details were analysed. Clients’ age ranged from
15 to 50 years with a mean of 30 years. Serodiscordant prevalence was 52 % and chi-square test suggests no significant
difference between serodiscordant and seroconcordant clients and their partners (p = 0.265). Serodiscordant rates were
closely associated trend wise with national HIV sero-prevalence rates and the median CD4+ count was 425 ul/mm3
(IQR: 290–606 ul/mm3). Similar proportion of clients (99 %) received testing and agreed to disclose status to their
partners. Yet, there was no association between clients agreement to disclose HIV status to their partners and these
partners getting tested and receiving results (p = 0.919). Significantly, 87 % of clients in concordant HIV positive
relationships appeared to be symptomatic (WHO clinical stage 3 or 4) compared to 13 % clients in HIV-discordant
relationships (p < 0.003). Client’s age and CD4+ count did not aptly predict serodiscordance (Wald = 0.011 and 0.436
respectively). However, the WHO clinical staging appeared to be a better predictor of serodiscordance and
concordance than other variables (Wald = 3.167).
Conclusions: The results suggest that clinical staging (WHO) could be a better predictor of client- partner pair
discordant or concordant HIV serostatus. Early partner testing and notification can avert seroconversion, hence properly
designed and mainstreamed interventions that target serodiscordant couples are essential.
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Background
Prevention of mother to child transmission (PMTCT)
is vital for HIV/AIDS control [1–3]. In developing
countries, antiretroviral (ARV) prophylaxis averted HIV
infection in 409,000 children between 2009 to 2011 [4].
However, PMTCT is not optimum in Nigeria, with lar-
gest number of new paediatric HIV infection globally
occurring here – averaging 60 000 yearly from 2009 to
2012 [5]. For enhanced PMTCT, mutual knowledge of
partner’s HIV status is ideal [6], yet clinicians fre-
quently have to presume that HIV-positive women have
partners whose status are either negative or unknown.
We introduce the term ‘serodiscordancy’ to encompass
serodiscordant and seroconcordant heterosexual couples.
Serodiscordant or serodiscordance applies when one part-
ner of an intimate couple pair’s HIV result is positive and
other negative. If positive HIV results are known for both,
this is a seroconcordant or seroconcordance relationship
[7]. A discordant status is particularly risky because regu-
lar coitus without condoms is more probable in stable
long-term partnerships (married or cohabiting).
Serodiscordance is documented as a growing source of
HIV-transmissions in sub-Saharan Africa (SSA) [8, 9], thus
averting intra-couple transmission could amply impact the
epidemic [10]. Proper condom use [11] diminishes expos-
ure and early ARV initiation lowers viral replication which
limits transmission of human immunodeficiency virus
type 1 (HIV-1) in serodiscordant couples [12, 13].
Unprecedented antiretroviral therapy scale up has im-
proved access for millions worldwide. In Nigeria, this
means rapidly expanding numbers of People Living With
HIV (PLWHIV) enrolled in treatment programs [14].
For PLWHIV, evaluating the effectiveness of existing
programs allows for development of context- specific
strategies that addresses their sexual/reproductive aspi-
rations, and attendant risks [15], including participation
in a HIV serodiscordant relationship.
Furthermore, in stigma-rife parts of SSA, gender directed
abuse may accompany disclosure of a HIV positive result
[16, 17]. Though aberrant social-cultural and gender power
constructs are plausible explanations, the availability of
sexually transmitted infections (STIs) control services in-
cluding pre-exposure prophylaxis must be considered
Several studies in Nigeria have examined serodiscor-
dance and disclosure [18–20], but these were largely
geographically-limited. From select PMTCT treatment
facilities across Nigeria, this paper explores associations
between certain predictors and serodiscordance among
pregnant HIV-positive clients and their partners.
Methods
Location
Nigeria is organized into six geo-political zones, which
encompass neighbouring states (see Additional file 1).
The study was conducted in 5 of the 6 geo-political zones
excluding the North East zone due to security challenges.
In July, 2013, locations providing comprehensive HIV/
AIDS treatment services to pregnant women and their
partners for at least one year were enrolled. Eventually, 62
ARV (known as comprehensive service delivery points)
spanning primary, secondary and tertiary level facilities
were eligible.
Population
All pregnant women aged ≥ 15 years enrolled in PMTCT
program in selected facilities in the study locations.
Based on National PMTCT guidelines, pregnancy in the
HIV positive woman is an indication for ARVs irrespect-
ive of CD4, VL or clinical stage [21].
Design
A retrospective performance evaluation that measures
Quality of Care (QoC) provided to HIV positive preg-
nant women and their exposed infants, particularly in
the children’s first 2 years of life, in a 6-month review
period (January 1st – June 30th, 2013).
Sampling technique
The QoC evaluation exercise included four (4) different
categories of women (inclusion criteria) which were:
i. HIV positive pregnant women identified in Antenatal
Care (ANC) in 6 months prior to the beginning of the
review period (July – December, 2012).
ii. Unbooked HIV positive pregnant women who
delivered at the facility in 6 months prior to the
beginning of the review period (July – December,
2012).
iii. All deliveries by HIV positive pregnant women
(booked and unbooked) during 6 months of the
review period (January 1st – June 30th, 2013).
iv. HIV positive pregnant women who delivered in the
facility 12 – 18 months prior to the beginning of the
review period (July 2011 – December 2012).
Unbooked women are those who appear for the first
time in the facility when in labour.
Sample frame was developed by applying the four in-
clusion criteria stated above to each audited patient’s
medical folders. The sampling method varied from site
to site, depending largely on the site’s information man-
agement system. For Electronic Medical Record enabled
sites (which includes patient IDs, up-to-date clinical and
other follow up information) all eligible sample of
PMTCT patients was generated and audited. For paper-
based medical record sites, a systematic random sam-
pling was used to generate the required sample of
PMTCT patients audited.
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Sample size
This was determined for each of the different sampling
methods applied for the two categories of sites men-
tioned above using the HIVQUAL [22] sampling meth-
odology (see Additional file 2). These relied on the
following 5 simple steps;
1. Determine the number of HIV+ pregnant women in
each category (i – iv) in the 6 months reference
period for each of categories i – iv (Xi - Xiv).
2. Determine PMTCT sample size for each of
categories i - iv (Yi – Y iv) from the HIVQUAL
sample size determination table (see Additional file 2).
3. Input the Y (Yi – Y iv) number of ANC IDs on the
Random Number List(RNL).
4. Divide the total number of HIV+ pregnant women
in each category (Xi - Xiv) by (Yi – Y iv) respectively.
Approximate (X/Y) to the nearest whole number N.
5. Identify every Nth HIV+ woman’s ID, impute them
serially into the RNL forms. Quality of PMTCT care
will be reviewed for women with these IDs.
Where ‘’X” is the total sample of eligible population
(Sample Frame) and ‘’Y” the sample size generated from
HIVQual sample size determination table.
Data collection
The QoC performance evaluation process involved use of
care and treatment service delivery indicators and entries
in national data collection tools (DCTs) to guide data ab-
straction from randomly selected pre-existing patients’
medical records. The four inclusion criteria stated in sec-
tion 2.4 were applied to each audited medical folders.
For the PMTCT program component of the exercise,
HIV negative pregnant women and HIV positive women
with incomplete partner data were excluded from the
sample of folders audited. Reliable and site specific data
from the following registers - the Antenatal Care (ANC),
HIV counselling and Testing, Delivery, Maternal, Partner,
Early Infant Diagnosis, Child follow-up and ARV were
reviewed and used to determine the pool of eligible sample
of patients audited. The inclusion and exclusion criteria
were applied on each step of the performance evaluation
audit.
Data analysis
Data was sorted, coded, keyed into Microsoft Access
database and exported to SPSS 20.0 for analysis. Results
were presented using charts, graphs and frequency ta-
bles. Descriptive statistics such as mean, frequencies and
percentages was used to describe and summarize find-
ings. Contingency tables were developed, logistic regres-
sion and chi-square statistics tested associations between
variables and level of significance (α = 0.05).
Ethical consideration
Ethical approval was obtained in line with the standard
ethical procedures from the United States Centers for
Disease Control and Prevention (CDC). The National
Research Health Ethics Committee (NRHEC) of the
Federal Ministry of Health Nigeria approved the pri-
mary survey. No clients were recruited for the PMTCT
performance evaluation.
Study abstraction forms collated data from pre-existing
client medical records and facility registers. Within facil-
ities, abstraction was performed only in secure areas and
data with or containing links to unique identifiers of study
subject were kept under lock and key, until these records
were appropriately returned to the facility records sec-
tions. All individuals involved in data abstraction and ana-
lysis received training on confidentiality procedures and
obtained Collaborative Institutional Training Initiative
(CITI) human subjects certification.
Results and discussion
Descriptive analysis
The records of a total of 2,499 HIV positive women were
sampled, but 544 (22 % of the total eligible population)
who met inclusion criteria for clients with matched part-
ner details was used in the analysis. Test for associations
of the continuous variables (Age, baseline CD4+ count
and WHO clinical staging) and dichotomous variables
(received HTC, agreement to notify partner i.e., disclos-
ure and clients who received ARV) were explored
(Table 1).
Approximately 78 % of clients with no available part-
ner information (i.e., no partner HIV status documented
in PMTCT partner register) were excluded. Poor docu-
mentation of partner HIV status in the PMTCT partner
register at the study sites may have impacted on the re-
sults of the analysis as evident with the significant Chi-
square goodness of fit χ2 (1) = 796.68, p = 0.001.
Serodiscordancy characteristics
Approximately 52 % (285) of total client-partner pairs
analysed were serodiscordant (i.e., HIV sero-positive
pregnant woman with HIV sero-negative partners) while
48 % (259) of same population was seroconcordant (HIV
sero-positive pregnant woman with HIV sero-positive
partners). No significant difference was observed be-
tween clients engaged in serodiscordant relationships or
Table 1 Proportion of total HIV clients by partners
Variables Frequency Percent Chi-Square
Client’s with no partners 1955 78 796.68 (p < 0.001)*
Client’s matched with partners 544 22
Total 2499 100
*Significant (P-value < 0.05)
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their seroconcordant counterparts, Chi-square goodness
of fit χ2 (1) = 796.68, p = 0.265. Low partner involvement
and poor site documentation of partner PMTCT data
may however account for the lack of difference in the
outcome of interest (Table 2).
Characteristics of geo-political regions
High serodiscordant rates were noted across 3 of the 5
(60 %) study locations. The affected geopolitical regions
are the South-South (SS) 60.2 %, North-Central (NC)
51.9 % and South-West (SW) 53.1 %. In contrast, high
seroconcordant rates were recorded in the North-West
(NW) 83.3 % and South-East (SE) 50.8 %. In general,
there was no significant association between belonging
to a serodiscordant or seroconcordant relationships with
geo-political regions; χ2 (1) = 6.147, p = 0.188 (Table 3).
The line graphs on prevalence by region shows no
distinct separation of clients in seroconcordant and
serodiscordant relationships. Peak prevalence rates of
seroconcordant (50.4 %) and serodiscordant (49.1 %)
clients and their partners were recorded in the North
Central region. This is consistent with the 2010 Na-
tional HIV Sero-prevalence Sentinels Survey (NHSS)
outcomes which report the highest HIV prevalence
the North Central (7.7 %) region (Fig. 1).
Line graphs of the 2010 NHSS [23] plotted alongside
the serodiscordance prevalence from this study across
the 5 study regions indicates a glove fit pattern. Highest
prevalence was in the NC with NHSS (7.7 %) and sero-
discordant prevalence (49.1 %). Lowest prevalence was
in NW with NHSS (2.1 %) and serodiscordant
prevalence (0.4 %). This correlates suggest that the
NHSS could serve as a proxy for estimating prevalence
of serodiscordancy among clients and their partners.
Thus, the NHSS could guide serodiscordant interven-
tion, extrapolation and or estimating prevalence of
Nigeria’s serodiscordancy (Fig. 2).
Clinical characteristics
Exactly 55 % of the study clients in seroconcordant rela-
tionships demonstrated CD4+ count less than 350 ul/mm3
compared to 49 % of clients in serodiscordant relation-
ships who have CD4 count greater than 350 ul/mm3.
However, there was no association between clients be-
ing in seroconcordant relationship and serodiscordant
relationships with CD4+ count; χ2 (1) = 0.143, p = 0.706
(Table 4).
In terms of WHO clinical staging, clients in serocon-
cordant relationships (87 %) appeared symptomatic (i.e.,
having a WHO clinical stage of 3 or 4) as compared to
52 % of the clients in serodiscordant relationships who
were asymptomatic (i.e., having a WHO clinical staging
of 1 or 2). The chi-square test suggest that there is a sig-
nificant but weak association between clients being in
seroconcordant or serodiscordant relationships with
WHO clinical staging; χ2 (1) = 8,751, p < 0.003, Phi coef-
ficient (φ) = −0.150.
Baseline CD4+ counts for 63 % (342) of all 544 clients in
the study were accounted for. Of this, the median CD4+
count was 425 ul/mm3 (IQR: 290–606 ul/mm3) (Fig. 3).
The CD4+ count distribution displayed a non – normal
spread with a Shapiro-Wilk's test = 0.093, p < 0.001, which
was significant at the 95 % confidence interval (CI). The
slope is left leaning (positive) with skew of 1.052 (standard
error = 0.132) and kurtosis of 2.426 (standard error =
0.263). A multi country trial among African serodiscor-
dant couples revealed high mortality rates at CD4
counts < 500 cells/μl with 8.9 deaths/1000 person years
at CD4 counts of 350–499 cells/μ [24].
The median baseline CD4+ count among clients in sero-
discordant relationship was 430.5 ul/mm3 compared to
Table 2 Proportion of serodiscordancy among HIV positive
pregnant women and their sero-negative partners
Variables Frequency Percent Chi-Square
Seroconcordant clients 259 48 796.68 (0.265)
Serodiscordant clients 285 52
Total 544 100
Table 3 Proportion of serodiscordancy by geo-political zones
Variables Total Seroconcordant Serodiscordant Chi-square
(p-value)
Symetric Measure
n % n % n % Cramer’s V Phi coefficient
South South 103 100 41 39.8 62 60.2 6.147 (0.188) .11
North Central 270 100 130 48.1 140 51.9
North West 6 100 5 83.3 1 16.7
South West 32 100 15 46.9 17 53.1
South East 132 100 67 50.8 65 49.2
Total 543 100 258 100 285 100
Significant (P-value < 0.05)
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414 ul/mm3 among clients in seroconcordant relationship
(Fig. 4). The boxplot displayed a non – normal distribu-
tion between the 2 distinct HIV Sero-status with a
Shapiro-Wilk’s test = 0.876, p < 0.001, which was signifi-
cant at the 95 % CI.
Age demographic and clients HIV disclosure characteristics
Client’s age distribution demonstrated Gaussian proper-
ties with an almost exact mean, median and mode. The
mean age of the study population was 30.3 ± 4.89 years
and ranged from 15 to 50 years (Fig. 5).
In terms of clients age, 80 % of the study clients in
seroconcordant relationship belong to the 15–19 years
category, making it the highest age group among Sero-
concordant clients, while 39 % belong to the 40–44 age
category, −the least. Among clients in serodiscordant
relationships, 62 % of the clients are in the 40–44 years
category- highest, while 20 % belong to the 15–19 age
Fig. 1 Trend lines showing pattern of serodiscordant and seroconcordant relationships across 5 geo-political regions
Fig. 2 Trend line showing pattern of National ANC HIV Sero-prevalence (NHSS) and serodiscordant prevalence across 5 geopolitical regions
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category, − least. The chi-square test of significant sug-
gests no association between clients in seroconcordant
relationship and serodiscordant relationships with Age
(Fig. 6).
Figure 6 shows the age disaggregated disclosure pat-
tern of clients. As seen across all ages’ majority stated
agreement to partner disclosure.
In terms of HIV testing and (HTC), less than two
thirds (53 %) of the clients in serodiscordant rela-
tionships received HIV testing while 47 % of clients
in seroconcordant relationships did not. 54 % of the
clients in serodiscordant relationships agreed to dis-
close their HIV status to their partners, while 46 %
of the clients in seroconcordant relationships re-
ported otherwise.
The outcome of HIV testing and counselling
(HTC) of PMTCT intervention in this study ap-
peared a better fit among serodiscordant clients
and their partners as compared to seroconcordant
clients and their partners. The chi-square test of sig-
nificance suggest no associations between these
groups regarding HTC and clients agreement to dis-
closure of HIV status respectively; χ2 (1) = 0.012 and
0.024, p = 0.911 and 0.877.
Clients disclosure of HIV status characteristics
Almost all (99 %) of study clients agreed to disclose their
HIV status to their partners. There was a significant dif-
ference between clients who agreed to partner disclosure
and clients who did not; χ2 (1) = 374.16, p < 0.001.
Table 4 Proportion of clinical characteristics
Variables Total Seroconcordant Serodiscordant Chi-square (p-value) Symetric measures
n % n % n % Cramer’s V Phi coefficient
Baseline CD4+ count 0.143 (0.706) 0.04
CD4 < 350 40 100 22 55.0 18 45.0
CD4 > 350 76 100 39 51.3 37 48.7
WHO clinical staging 8.751 (0.003)* −0.15
Asymptomatic 373 100 178 47.7 195 52.3
Symptomatic 15 100 13 86.7 2 13.3
*Significant (P-value < 0.05)
Fig. 3 Histogram showing median distribution of client’s total baseline CD4+ count
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Fig. 4 Boxplot showing median distribution of client’s total baseline CD4+ count with clients HIV sero-status
Fig. 5 Histogram showing age distribution of study clients
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Efficient and effective HIV testing and counselling ser-
vices implemented at the study sites may account for the
differences (Table 5).
It is evident that across all study regions, there is
strong momentum among majority of study clients to
disclose their HIV status, however a few of these clients
(3 %) in the South- South region reported otherwise.
The Pearson chi-square test of association suggests no
significant association between clients disclosure of HIV
status and study regions; χ2 (1) = 7.965, p = 0.093. To im-
prove objective measures that ensure good HTC out-
comes, this result underlies the necessity by health
providers to initiate innovative processes to verify that
clients who indicated agreement to partner disclosure
actually follow through or are supported to achieve this
(Table 6).
The cross tabulation statistics output of clients dis-
closure status was 99.7 % between clients who received
HTC, and clients agreed to disclosure of HIV status
and suggests high chances or likelihood of partners
getting tested and counselled in the PMTCT program.
However, the chi-square statistics suggests no associa-
tions between these variables; χ2 (1) = 0.010, p = 0.919
(Table 7).
Logistic regression
A predictive model, binomial logistic regression was
performed to ascertain the effects of Age, CD4+ count
and WHO Clinical staging on the likelihood that partic-
ipants were in concordant or discordant relationships.
The logistic regression model was not statistically
significant, Chi-Square χ2 (4) = 4.012, p > 0.05. The
model explained 19 % (Nagelkerke R2) of the variance
in serodiscordancy and only correctly classified 56.3 %
of cases. Sensitivity was 94.6 %, specificity was low
at 14.1 %, positive predictive value was 54.9 % and
negative predictive value was 70.4 %. Client’s age and
CD4+ count did not aptly predict serodiscordance
(Wald = 0.011 and 0.436 respectively). However, the
WHO clinical staging appeared to be a better predictor
of serodiscordancy than other explanatory variables
(Wald = 3.167) with an odds ratio of 0.234 (95 %
CI: 0.047 to 1.159) (Table 8).
The disclosure process in the national HCT guidelines
neither elicits partners’ age nor enforces enrolment/ARV
status of HIV + partners [7] and weren’t available for
analysis. The small sample size of the explanatory vari-
able- WHO clinical stage (less than 15 for the WHO
symptomatic category) could have affected the reliability
of the Sig estimates, as it does not meet minimum statis-
tical recommendations of at least 15 cases.
Limitations
Data quality likely influenced findings, Nigeria’s health
data management systems require urgent improvement.
The retrospective methodology restricted research to
use of historical data. Consequently, other important
Fig. 6 Percent distribution of clients who agreed to partner disclosure by age
Table 5 Proportion of partner disclosure among study clients
Variables Frequency Percent Chi-square
Agreed to partner disclosure 386 99 374.16 (p < 0.001)*
Did not agree to
partner disclosure
4 1
*Significant (P-value < 0.05)
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Table 6 Proportion of partner disclosure across the study regions
Variables Agreed to partner disclosure Did not agree to partner disclosure Chi-square
(p-value)
Symmetric measure
n % n % Cramer's V Phi coefficient
South -South 94 96.9 3 3.1 7.965 (0.093) 0.14
North Central 226 100 0 0.0
North West 4 100 0 0.0
South West 28 100 0 0.0
South East 33 97.1 1 2.9
Total 385 99 4 1.0
Significant (P-value < 0.05)
Table 7 Proportion of clients who agreed to disclosure of HIV status by their partners who received testing and counselling
Variables Total Agreed to disclosure of HIV status Did not agree to disclosure of HIV status Chi-square
(p-value)
Symmetric measures
n % n % n % Phi coefficient Cramer's V
Partners tested and received results 0.010 (0.919) 0.005
No 4 100 4 100 0 0
Yes 385 100 384 99.7 1 0.3
Significant (P-value < 0.05)
Table 8 Logistic regression model
Model summary
Step −2 Log likelihood Cox & Snell R Square Nagelkerke R square
1 389.005a 0.014 0.019
Hosmer and Lemeshow test
Step Chi-square df Sig.





Step 1 HIV Sero-status Concordance 19 116 14.1
Serodiscordance 8 141 94.6
Overall Percentage 56.3
The cut value is .500b
Variables in the equation
B S.E. Wald df Sig. Exp(B) 95 % C.I.
for EXP(B)
Lower Upper
Step 1a WHO_clinical_stage(1) −1.453 0.816 3.167 1 0.075 0.234 0.047 1.159
CD4+ count 0 0 0.436 1 0.509 1 0.999 1.001
Age −0.003 0.024 0.011 1 0.915 0.997 0.951 1.046
Constant 0.363 0.781 0.216 1 0.642 1.438
Bold data is the test statistics predicts serodiscordant or concodant partner relationaship, since the wald coefficient 3.167 is greater than 0
aEstimation terminated at iteration number 4 because parameter estimates changed by less than .001
bVariable(s) entered on step 1: WHO_clinical_stage, CD4_raw, and Age
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variables particularly partner’s age, ARV status/regimen,
frequency and route of coitus were not available for
analysis.
Conclusions
In conclusion, the regression model was a poor fit and
indicates no significant association between the sus-
pected determinants and serodiscordance. However, the
WHO clinical staging appeared to be a better predictor
of serodiscordancy than the other explanatory variables.
For detailed explanation see logistic regression section
above.
Effective disclosure begins at pre testing and runs
through post counselling as explained in national guide-
lines. The algorithm contained is adequate on adhering
to confidentiality and ensuring psychosocial support
[25]. Urgent attention is required to create, mainstream
and harmonize male partner data in relation to pregnant
women accessing PMTCT.
Likewise, research is essential on partners of HIV posi-
tive males (females in heterosexual partnerships and
male partners of Men who have sex with Men-MSM).
Associations with viral load, gestational age, nutrition,
genetics and parity are other important indices or pre-
dictors and should be explored in subsequent studies.
Early partner testing and notification can avert serocon-
version, thus expanding/redesigning interventions to ac-
commodate serodiscordant couples is essential. Flexible
policies on use of data generated by PEPFAR implement-
ing partners (USAID/CDC) program for serodiscordant
studies are helpful.
Serodiscordancy findings should be tracked in the na-
tional Mode of Transmission (MOT) reports across all
the risk groups stated. Eventually, serodiscordant rates
have methodological and statistical implications for rely-
ing on ANC HIV sero-prevalence as proxy for estimating
national HIV prevalence.
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